Efpeglenatide reduces MACE, kidney events in high-risk patients with T2D
23 Jul 2021
bởiRoshini Claire Anthony
In patients with type 2 diabetes (T2D) with cardiovascular (CV) risk factors or impaired kidney function, weekly doses of the exendin-based GLP-1* receptor agonist (RA) efpeglenatide may reduce their risk of major adverse cardiovascular events (MACE) or kidney outcomes, according to findings from the AMPLITUDE-O trial presented at ADA 2021.
Efpeglenatide reduces MACE, kidney events in high-risk patients with T2D
23 Jul 2021